Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

C-RAD has decided to repurchase own class B shares

CRAD BRegulatoriskt pressmeddelande22.10.2026 klo 08.30

Ladda ner börsmeddelandet

C-RAD AB (publ) (“C-RAD”), a global leader in surface guided radiation therapy (SGRT), announces today that the Board of Directors, supported by the authorization from the 2026 Annual General Meeting, has decided to repurchase a maximum of 600,000 class B shares for an amount of up to SEK 20 million during the period up to the 2027 Annual General Meeting (the “Repurchase Program”). The purpose of the Repurchase Program is to optimize C-RAD’s capital structure by reducing the share capital by canceling repurchased class B shares and consequently the Board of Directors of C-RAD intends to propose to the 2027 Annual General Meeting to resolve on this.

The Repurchase Program will be implemented by Pareto Securities AB on behalf of C-RAD. Pareto Securities AB will make its trading decisions regarding the B shares independently of and without influence from C-RAD and otherwise in accordance with the applicable rules and regulations of Nasdaq's rules and regulations for issuers of shares on the main market (the "Rules"), Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation").

The repurchase program is subject to the following conditions:

Repurchases may be made on one or more occasions during the period until the 2027 Annual General Meeting. During this period, C-RAD may repurchase a maximum of 600,000 of its own class B shares for an amount of up to 20 million SEK.
Repurchases shall be made on Nasdaq Stockholm and in accordance with the Rules and Regulations, MAR and the Safe Harbour Regulation.
Repurchases on Nasdaq Stockholm shall be made at a price per share within the price range applicable at any given time, which is the interval between the highest bid price and the lowest ask price, and in addition, the price restrictions in the Safe Harbour Regulation shall be observed.
Repurchases may only be made in compliance with the quantity restrictions for the purchase of own shares specified in the Rules and in the Safe Harbour Regulation.
In accordance with the authorization from the 2026 Annual General Meeting, C-RAD's holding of own shares may not exceed 10 percent of all outstanding shares in C-RAD.
Payment for the repurchase of own class B shares shall be made in cash.

The purpose of the Repurchase Program is to optimize C-RAD's capital structure by reducing the share capital with the cancellation of repurchased class B shares, and consequently the Board of Directors of C-RAD intends to propose to the 2027 Annual General Meeting to resolve on this. As previously communicated, C-RAD's financial targets, in the medium term, are for average organic growth to exceed 10 percent and the operating margin (EBIT margin) to reach 25 percent. At least 30 percent of the net profit shall be returned to shareholders.

The total number of outstanding shares is 33,766,935, divided into 862,887 class A shares and 32,904,048 class B shares. C-RAD currently holds 785,500 of its own class B shares, corresponding to approximately 2.3 percent of the total number of its own shares in C-RAD.

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com